<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394355</url>
  </required_header>
  <id_info>
    <org_study_id>P03418</org_study_id>
    <secondary_id>Doc ID: 3387777;</secondary_id>
    <secondary_id>EUDRACT No: 2004-002930-21;</secondary_id>
    <nct_id>NCT00394355</nct_id>
  </id_info>
  <brief_title>Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)</brief_title>
  <official_title>Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, parallel-group, active-controlled, double-blind study
      evaluating the effects of mometasone furoate (MF) dry powder inhaler (DPI) on bone mineral
      density (BMD) in subjects with asthma. The mean percent change in lumbar spine BMD from the
      averaged baseline value (the average of the two scan results prior to treatment) to the
      endpoint of treatment time point (the average of the last two valid post-baseline scan
      results during treatment) for the comparison of MF DPI 400 mcg daily in the evening versus
      montelukast (ML) 10 mg daily in the evening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time Point</measure>
    <time_frame>Baseline and up to ~ one year of treatment</time_frame>
    <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in the Left Total Femur From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</measure>
    <time_frame>Baseline and up to ~ one year of treatment</time_frame>
    <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in the Femoral Neck BMD From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</measure>
    <time_frame>Baseline and up to ~ one year of treatment</time_frame>
    <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Change From Baseline to Endpoint in FEV1 (Forced Expiratory Volume in One Second).</measure>
    <time_frame>Baseline and up to ~ one year of treatment</time_frame>
    <description>Mean percent change from Baseline (the last non-missing value prior to treatment) in pulmonary function test FEV1 from in-office visits and at Endpoint (last non-missing postbaseline value carried forward)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">566</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF DPI 400 mcg once a day (QD) in the evening (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF DPI 200 mcg QD PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ML 10 mg QD PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate dry powder inhaler</intervention_name>
    <description>400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate dry powder inhaler</intervention_name>
    <description>200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate hydrofluoroalkane (HFA)</intervention_name>
    <description>250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Flovent HFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>10 mg given once daily in the evening by mouth for 1 year.</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent, adhere to schedules.

          -  Inform usual treating medical doctor (MD) of study participation.

          -  Female 18 to 40, male 18 to 50, any race.

          -  &gt;=3-month asthma history.

          -  Never treated with inhaled corticosteroids (ICS) for asthma or not have taken ICS for
             ≥3 months prior to Screening.

          -  Prebronchodilator forced expiratory volume (liters) in 1 second (FEV1) &gt;=60% &amp; &lt;=90%
             predicted at both Screening &amp; Baseline, when all restricted medications withheld.

          -  Prior to randomization, demonstrate increase in absolute FEV1 of &gt;=12%, with absolute
             volume increase of &gt;=200 mL, after reversibility testing.

          -  Lab tests normal/acceptable to investigator/sponsor. Electrocardiogram (ECG) performed
             at screening or &lt;30 days of screening normal/acceptable to investigator. Chest x-ray
             performed at screening or &lt;12 months of screening normal/acceptable to investigator.

          -  25-hydroxy vitamin D level &gt;=15 ng/mL. If &lt;15, re-tested after taking calcium plus
             vitamin D for 4 weeks.

          -  Free of significant disease (other than asthma) known to affect bone mineral
             metabolism including renal disease, unstable hyperthyroidism or other
             endocrinopathies, Paget's disease, osteoporosis, malabsorption, or others that could
             interfere with study evaluations (eg scoliosis, metal pins, calcification in
             spine/femur).

          -  Women of childbearing potential must use birth control. Includes: hormonal
             contraceptive, intra-uterine device (IUD); condom in combination with spermicide;
             monogamous relationship with male who had vasectomy or is using condom. Started method
             ≥3 months prior to Screening (exception condom), &amp; agree to continue for duration.
             Women who are not currently sexually active must agree/consent to using double-barrier
             method if become active. Females must have negative serum pregnancy test at Screening.

          -  2 valid scans, as confirmed by local dual energy x-ray absorptiometry (DXA) center,
             for lumbar spine, left total femur, &amp; femoral neck prior to randomization. Valid scans
             will be 2 scans of same region, performed on same day, that agree within 5% &amp; scans
             are technically satisfactory (eg correct scan mode, no artifacts present, correct
             region).

        Exclusion Criteria:

          -  &gt;12 inhalations/day of salbutamol on 2 consecutive days between Screening &amp; Baseline.

          -  Increase/decrease in FEV1 of &gt;=20% between Screening &amp; Baseline.

          -  Treated with methotrexate, cyclosporin, gold, or other cytotoxic agents, for asthma or
             concurrent condition within last 3 months.

          -  Pipe/cigar smoking history.

          -  Smoker/ex-smoker who smoked within previous year or has smoking history ≥10
             pack-years.

          -  Upper/lower respiratory tract infection within 2 weeks prior to Screening &amp; Baseline.
             Can be rescheduled.

          -  &gt;14 days of oral steroids within previous 12 months or required burst of systemic
             steroids within previous month.

          -  Ever required ventilator support for respiratory failure secondary to asthma.

          -  Treated in emergency room (ER) for asthma exacerbation or admitted to hospital for
             management of airway obstruction on 1 occasion in last 3 months or on &gt;=2 occasions
             within last 6 months.

          -  Chronic bronchitis, bronchiectasis, emphysema or cystic fibrosis.

          -  Participated in study within last 30 days.

          -  Allergic to/intolerant of ICS, beta-agonists, or drugs/excipients in study.

          -  Average of 2 lumbar spine (L1-L4) scans at Screening is &gt;2 standard deviations below
             normal.

          -  Condition that might affect ability to ambulate normally, (ie major surgical
             procedure). Condition that may interfere with BMD measurement.

          -  History of renal, hepatic, cardiovascular, metabolic, neurologic, hematologic,
             respiratory, gastrointestinal, cerebrovascular, or other which could interfere with
             study or require treatment which might interfere (eg calcium urolithiasis or
             absorptive hypercalcuria, insulin dependent diabetes, cancer within last 10 years
             (except basal cell carcinoma), active hepatitis, coronary artery disease, stroke,
             rheumatoid arthritis, human immunodeficiency virus (HIV), or respiratory conditions
             such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic
             fibrosis. Others which are well-controlled &amp; stable (eg hypertension, arrhythmia,
             subjects on stable thyroid hormone replacement for at least 3 months whose thyroid
             stimulating hormone (TSH) levels are normal) may be allowed.

          -  Treated within last year with drug known to interfere with bone metabolism including:
             bisphosphonates, estrogens such as depot injectables (estrogens used in oral combined
             hormonal contraceptives are allowed if dose is stable throughout), high-dose fluoride,
             &amp; thyroid replacement hormones (if not stabilized).

          -  History &amp;/or presence of intraocular pressure in either eye &gt;=22 mm Hg, glaucoma, &amp;/or
             posterior subcapsular cataracts. History &amp;/or presence of nuclear cataract or
             undergone bilateral lens extraction may be eligible.

          -  The subject has undergone incisional or intraocular surgery in which the natural lens
             is still present in the eye.

          -  The subject has a history of penetrating trauma to both eyes.

          -  The subject has one or more of the following lens opacities classification system
             version III (LOCS III) grades at screening: nuclear opalescence (NO) &gt;=3.0, nuclear
             color (NC) &gt;=3.0, cortical (C) &gt;=2.0, posterior (P) &gt;=0.5.

          -  Pregnant, breast-feeding, or postmenopausal women. Amenorrhea &gt;6 months will be
             excluded (exception hysterectomy). Bilateral oophorectomy excluded.

          -  Relevant abnormal Baseline vital sign.

          -  Body mass index (BMI) &gt;35 kg/m2.

          -  HIV positive (testing not performed).

          -  Alcoholic or illicit drug abuser.

          -  Evidence of oropharyngeal candidiasis at Baseline with or without treatment. If
             evidence at Screening, may be treated as appropriate &amp; visit can be scheduled upon
             resolution. If evidence at Baseline Visit, may be treated as appropriate &amp; visit can
             be rescheduled upon resolution.

          -  Normal sleep/wake cycle is inverted (eg night shift workers).

          -  Taken restricted medications prior to Screening.

          -  Cannot adhere to prohibited &amp; permitted concomitant medications.

          -  No subject may participate in this same study at another site or simultaneously in any
             other study.

          -  No person directly associated with administration of study may participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Venezuela</country>
  </removed_countries>
  <results_reference>
    <citation>Maspero J, Backer V, Yao R, Staudinger H, Teper A. Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma. J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):649-55.e1. doi: 10.1016/j.jaip.2013.07.011. Epub 2013 Oct 8.</citation>
    <PMID>24565713</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <results_first_submitted>October 22, 2010</results_first_submitted>
  <results_first_submitted_qc>February 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2011</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MF DPI 200 mcg QD PM</title>
          <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
        </group>
        <group group_id="P2">
          <title>MF DPI 400 mcg QD PM</title>
          <description>MF DPI 400 mcg QD PM for 1 year</description>
        </group>
        <group group_id="P3">
          <title>FP MDI 250 mcg BID</title>
          <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
        </group>
        <group group_id="P4">
          <title>ML 10 mg QD PM</title>
          <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal - unrelated to drug</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal - related to drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF DPI 200 mcg QD PM</title>
          <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
        </group>
        <group group_id="B2">
          <title>MF DPI 400 mcg QD PM</title>
          <description>MF DPI 400 mcg QD PM for 1 year</description>
        </group>
        <group group_id="B3">
          <title>FP MDI 250 mcg BID</title>
          <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
        </group>
        <group group_id="B4">
          <title>ML 10 mg QD PM</title>
          <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="142"/>
            <count group_id="B5" value="566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="7.8"/>
                    <measurement group_id="B2" value="29.8" spread="8.1"/>
                    <measurement group_id="B3" value="28.2" spread="6.9"/>
                    <measurement group_id="B4" value="28.2" spread="7.1"/>
                    <measurement group_id="B5" value="29.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time Point</title>
        <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
        <time_frame>Baseline and up to ~ one year of treatment</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF DPI 200 mcg QD PM</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
          </group>
          <group group_id="O2">
            <title>MF DPI 400 mcg QD PM</title>
            <description>MF DPI 400 mcg QD PM for 1 year</description>
          </group>
          <group group_id="O3">
            <title>FP MDI 250 mcg BID</title>
            <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
          </group>
          <group group_id="O4">
            <title>ML 10 mg QD PM</title>
            <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time Point</title>
          <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
          <population>All randomized participants</population>
          <units>percentage of BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.56"/>
                    <measurement group_id="O2" value="0.9" spread="2.56"/>
                    <measurement group_id="O3" value="1.1" spread="2.56"/>
                    <measurement group_id="O4" value="1.2" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way analysis of variance (ANOVA) model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way ANOVA model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.644</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in the Left Total Femur From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</title>
        <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
        <time_frame>Baseline and up to ~ one year of treatment</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF DPI 200 mcg QD PM</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
          </group>
          <group group_id="O2">
            <title>MF DPI 400 mcg QD PM</title>
            <description>MF DPI 400 mcg QD PM for 1 year</description>
          </group>
          <group group_id="O3">
            <title>FP MDI 250 mcg BID</title>
            <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
          </group>
          <group group_id="O4">
            <title>ML 10 mg QD PM</title>
            <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Left Total Femur From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</title>
          <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
          <population>All randomized participants</population>
          <units>percentage of BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.00"/>
                    <measurement group_id="O2" value="0.2" spread="2.00"/>
                    <measurement group_id="O3" value="0.2" spread="2.00"/>
                    <measurement group_id="O4" value="0.5" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way ANOVA model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.359</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way ANOVA model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.390</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in the Femoral Neck BMD From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</title>
        <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
        <time_frame>Baseline and up to ~ one year of treatment</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF DPI 200 mcg QD PM</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
          </group>
          <group group_id="O2">
            <title>MF DPI 400 mcg QD PM</title>
            <description>MF DPI 400 mcg QD PM for 1 year</description>
          </group>
          <group group_id="O3">
            <title>FP MDI 250 mcg BID</title>
            <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
          </group>
          <group group_id="O4">
            <title>ML 10 mg QD PM</title>
            <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Femoral Neck BMD From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point</title>
          <description>The averaged baseline value is the average of the two scan results prior to treatment. The endpoint of treatment time point is the average of the last two valid post baseline BMD scans during the treatment period carried forward.</description>
          <population>All randomized participants</population>
          <units>percentage of BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.17"/>
                    <measurement group_id="O2" value="0.4" spread="3.17"/>
                    <measurement group_id="O3" value="-0.4" spread="3.17"/>
                    <measurement group_id="O4" value="-0.2" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way ANOVA model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least squares mean percent changes were obtained from the two-way ANOVA model with treatment and BMD scan center effects. Results shown use percent change as a response.
Pooled Standard deviation from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Change From Baseline to Endpoint in FEV1 (Forced Expiratory Volume in One Second).</title>
        <description>Mean percent change from Baseline (the last non-missing value prior to treatment) in pulmonary function test FEV1 from in-office visits and at Endpoint (last non-missing postbaseline value carried forward)</description>
        <time_frame>Baseline and up to ~ one year of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MF DPI 200 mcg QD PM</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
          </group>
          <group group_id="O2">
            <title>MF DPI 400 mcg QD PM</title>
            <description>MF DPI 400 mcg QD PM for 1 year</description>
          </group>
          <group group_id="O3">
            <title>FP MDI 250 mcg BID</title>
            <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
          </group>
          <group group_id="O4">
            <title>ML 10 mg QD PM</title>
            <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline to Endpoint in FEV1 (Forced Expiratory Volume in One Second).</title>
          <description>Mean percent change from Baseline (the last non-missing value prior to treatment) in pulmonary function test FEV1 from in-office visits and at Endpoint (last non-missing postbaseline value carried forward)</description>
          <units>percentage of FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.43"/>
                    <measurement group_id="O2" value="0.38" spread="0.43"/>
                    <measurement group_id="O3" value="0.31" spread="0.43"/>
                    <measurement group_id="O4" value="0.19" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least square means and Pstd (pooled standard deviations) are obtained from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Least square means and Pstd (pooled standard deviations) are obtained from the ANOVA model with treatment effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MF DPI 200 mcg QD PM</title>
          <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg once daily (QD) in the evening (PM) for 1 year</description>
        </group>
        <group group_id="E2">
          <title>MF DPI 400 mcg QD PM</title>
          <description>MF DPI 400 mcg QD PM for 1 year</description>
        </group>
        <group group_id="E3">
          <title>FP MDI 250 mcg BID</title>
          <description>Fluticasone proprionate (FP) metered dose inhaler (MDI) 250 mcg twice daily (BID) for 1 year</description>
        </group>
        <group group_id="E4">
          <title>ML 10 mg QD PM</title>
          <description>Montelukast (ML) 10 mg QD PM for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lenticular opacities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" events="28" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="140"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" events="19" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E2" events="45" subjects_affected="27" subjects_at_risk="137"/>
                <counts group_id="E3" events="40" subjects_affected="26" subjects_at_risk="147"/>
                <counts group_id="E4" events="32" subjects_affected="23" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="140"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" events="15" subjects_affected="12" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E2" events="28" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" events="21" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="55" subjects_affected="22" subjects_at_risk="140"/>
                <counts group_id="E2" events="38" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" events="37" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E4" events="93" subjects_affected="21" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" events="35" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" events="15" subjects_affected="7" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator (PI) agrees not to publish or publicly present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide to the sponsor, 30 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, PI agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

